BAGNEUX, France, Dec. 10, 2015 (GLOBE NEWSWIRE) -- First Experimental Results for the Treatment of Colitis with Viaskin® will be presented at the Crohn's & Colitis Foundation of America's 2015 Advances in IBD Conference (AIBD)
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today announced that a communication on experimental results on the use of Epicutaneous Immunotherapy (EPIT®) in a model of Crohn's disease will be presented at the Crohn's & Colitis Foundation of America Advances in Inflammatory Bowel Diseases (AIBD) on December 10-12, 2015, in Orlando, Florida.
A "First Evidence for the Treatment of Colitis by Epicutaneous Immunotherapy in a Murine Model" will be presented by Dr. David Dunkin, Assistant Professor in the Division of Pediatric Gastroenterology at The Icahn School of Medicine, at the Mount Sinai in New York, at an Oral Presentation on Saturday, December, 12, 2015 at 12.00 pm (local time). The abstract will also be available for viewing online at http://www.advancesinibd.com and published in Inflammatory Bowel Diseases, February 2016 Issue.
Crohn's disease patients have a defect in inducing T-regulatory cells (Treg) via the gut. When Tregs are generated externally in response to food antigen and infused into patients, they suppress inflammation in Crohn's via bystander suppression (Desreumaux et al., Gastroenterology, 2012). This study was conducted on C57Bl/6 mice exposed epicutaneously for 48 hours once a week for 3 weeks to Viaskin patches containing ovalbumin (Viaskin-OVA). This experiment assessed that Tregs could be induced by applying antigen to intact skin using an epicutaneous delivery device, Viaskin®, and that after their migration to the gut, Tregs could abrogate colitis via bystander suppression. Epicutaneous tolerance induction could have the potential to treat Crohn's disease and further preclinical and clinical studies need to be conducted.
DBV Technologies and The Icahn School of Medicine at Mount Sinai entered into a research collaboration in February 2014 to investigate the efficacy of EPIT® using Viaskin® for the treatment of Crohn's disease.
Dr. David Dunkin, Assistant Professor in the Division of Pediatric Gastroenterology at The Icahn School of Medicine at the Mount Sinai Hospital said: "I am excited to present our data that may eventually translate into a new option for the treatment of Crohn's disease. What is most encouraging is that this therapy targets improving the regulatory capacity of the immune system and thus avoids immuno-suppression and its potential side effects."
Dr. Hugh Sampson, Chief Scientific Officer of DBV Technologies, said: "We are eager to explore the potential regulatory effects of this novel therapeutic platform and are very encouraged by the results of this study, which may lead to a safer and more effective way to treat this debilitating disease."
About Crohn's disease Crohn's disease is a chronic inflammatory disease of the gastrointestinal tract, mainly characterized by abdominal pain, diarrhea and various digestive and non-digestive complications. There are no medications or surgical procedures that can cure Crohn's disease. One in five people with Crohn's are admitted to a hospital each year, and as many as half of those suffering from the disease will require surgery over a ten-year period. The incidence of Crohn's is increasing, especially in young children and infants. Both men and women can be affected by Crohn's disease, which is usually diagnosed between the ages of 15 - 30.
About DBV Technologies DBV Technologies created the Viaskin® patch, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV's method of delivering biologically active compounds to the immune system through intact skin while avoiding compound transfer to the blood. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergy patients, for which there are currently no approved treatments. DBV's food allergy programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk and preclinical development of Viaskin Egg. DBV is also pursuing a human proof concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis and exploring potential applications of its platform in vaccines and for the treatment selected immune diseases with unmet medical needs. DBV Technologies has global headquarters in Paris, France and New York, NY, USA. Company shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com
Forward Looking Statements This press release contains forward-looking statements, including statements about the potential safety and efficacy of Epicutaneous Immunotherapy (EPIT®) via Viaskin® and the Company's preclinical and clinical development plans. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. The Company's product candidates have not been approved for sale in any jurisdiction. Among the factors that could cause actual results to differ materially from those described or projected herein are uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, the risk that historical preclinical results may not be predictive of future clinical trial results, and the risk that historical clinical trial results may not be predictive of future trial results. A further list and description of these risks, uncertainties and other risks can be found in the Company's regulatory filings with the French Autorité des Marchés Financiers, the Company's Securities and Exchange Commission filings and reports, including in the Company's Annual Report on Form 20-F for the year ended December 31, 2014 and future filings and reports by the Company. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release, whether as a result of new information, future events or circumstances or otherwise.
|DBV Technologies Contacts|
|Nathalie Donne Director, Corporate Communication & Business Development Tél. : +33(0)1 55 42 78 72 firstname.lastname@example.org|| Susanna Mesa VP Finance, US Investor Relations & Strategy |
Tél. : +1 212-271-0861
|DBV Technologies Media Contacts US & Europe|
| Marion Janic |
Rooney & Associates Tél. : +1-212-223-4017 email@example.com
| Caroline Carmagnol |
Alize RP - Relation Presse
Tél. : +33(0)6 64 18 99 59
PDF Version http://hugin.info/156437/R/1972519/721458.pdf